Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Breast 5Other hematologic neoplasm 4Lymphoid 4Tumor-Agnostic 3Thoracic 3Head & Neck 3Gynecologic 3Other solid neoplasm 2Sarcoma 1NET 1Myeloid 1Endocrine 1Dermatologic 1CNS 1

Conditions

Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × MK 2206 × Head & Neck × Clear all
NCT01604772 2019-05-01

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 7 charts
Head & Neck

Salivary Gland Neoplasms

NCT01349933 2017-12-05

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 11 charts
Head & Neck

Recurrent Squamous Cell Carcinoma of the Nasopharynx

NCT01370070 2017-01-13

MC1079

Chinese University of Hong Kong

Phase 2 Completed
12 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡